Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR/Cas9 system
Microbiology Spectrum · 02.04.2024 · 12 (4)
DOI: 10.1128/spectrum.03884-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.04.2024. Verfasst von Haijie Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joint International Research Laboratory of Agriculture and Agri-Product Safety of Ministry of Education of China, Yangzhou University, Yangzhou, Chin…. Hauptthemen laut MEDLINE: Escherichia coli Infections, Escherichia coli Proteins. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), JST | Jiangsu Provincial Key Research and Development Program (Key Technologies R&D Program of Jiangsu Province).
Abstract (Originalsprache)
Tigecycline and colistin were referred to as the “last resort” antibiotics in defending against carbapenem-resistant, Gram-negative bacterial infections, and are currently widely used in clinical treatment. However, the emergence and prevalence of plasmid-mediated tet (X4) and mcr-1 genes pose a serious threat to the therapeutic application of tigecycline and colistin, respectively. In this research, a tigecycline- and colistin-resistant bacteria resensitization system was developed based on efficient and specific DNA damage caused by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9 (Cas9) nucleases. A conjugation method was used to deliver the resensitization system, which harbors two single-guide RNAs targeting tet (X4) and mcr-1 genes and constitutively expressed Cas9. The conjugation efficiency was nearly 100% after conjugation condition optimization in vitro , and the resensitivity efficiency for clinical isolates was over 90%. In addition, when performing resensitization in vivo , the resistance marker was replaced with a glutamate-based, chromosomal, plasmid-balanced lethal system to prevent the introduction of additional resistance genes in clinical settings, making this strategy a therapeutic approach to combat the in vivo spread of antibiotic resistance genes (ARGs) among bacterial pathogens. As a proof of concept, this resensitive system can significantly decrease the counts of tigecycline- and colistin-resistant bacteria to 1% in vivo . Our study demonstrates the efficacy and adaptability of CRISPR-Cas systems as powerful and programmable antimicrobials in resensitizing tet (X4)- and mcr-1- mediated, tigecycline- and colistin-resistant strains, and opens up new pathways for the development of CRISPR-based tools for selective bacterial pathogen elimination and precise microbiome composition change. IMPORTANCE The emergence of plasmid-encoded tet (X4) and mcr-1 isolated from human and animal sources has affected the treatment of tigecycline and colistin, and has posed a significant threat to public health. Tigecycline and colistin are considered as the “last line of defense” for the treatment of multidrug-resistant (MDR) Gram-negative bacterial infections, so there is an urgent need to find a method that can resensitize tet (X4)-mediated tigecycline-resistant and mcr-1 -mediated colistin-resistant bacteria. In this study, we developed a glutamate-based, chromosomal, plasmid-balanced lethal conjugative CRISPR/Cas9 system, which can simultaneously resensitize tet (X4)-mediated tigecycline-resistant and mcr-1 -mediated colistin-resistant Escherichia coli . The counts of tigecycline- and colistin-resistant bacteria decreased to 1% in vivo after the resensitization system was administered. This study opens up new pathways for the development of CRISPR-based tools for selective bacterial pathogen elimination and precise microbiome composition change.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint International Research Laboratory of Agriculture and Agri-Product Safety of Ministry of Education of China, Yangzhou University, Yangzhou, China.
- College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China.
- Institute of Comparative Medicine, Yangzhou University, Yangzhou, China.
ORCID-Profile: Haijie Zhang, Yuan Liu, Zhiqiang Wang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- JST | Jiangsu Provincial Key Research and Development Program (Key Technologies R&D Program of Jiangsu Province)
Zitieren
APA
Zhang, H., Chen, B., Wang, Z., Peng, K., Liu, Y., & Wang, Z. (2024). Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR/Cas9 system. Microbiology Spectrum, 12(4). https://doi.org/10.1128/spectrum.03884-23
Vancouver
Zhang H, Chen B, Wang Z, Peng K, Liu Y, Wang Z. Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR/Cas9 system. Microbiology Spectrum. 2024;12(4). doi:10.1128/spectrum.03884-23
BibTeX
@article{Zhang2024,
author = {Zhang, Haijie and Chen, Bo and Wang, Zeyu and Peng, Kai and Liu, Yuan and Wang, Zhiqiang},
title = {Resensitizing tigecycline- and colistin-resistant Escherichia coli using an engineered conjugative CRISPR/Cas9 system},
journal = {Microbiology Spectrum},
year = {2024},
volume = {12},
number = {4},
doi = {10.1128/spectrum.03884-23}
}
EUVIMED